Public Meeting on Patient-Focused Drug Development for Stimulant Use Disorder - 03/10/2020 - 03/10/2020 | FDA

Public Meeting on Patient-Focused Drug Development for Stimulant Use Disorder - 03/10/2020 - 03/10/2020 | FDA





Public Meeting on Patient-Focused Drug Development for Stimulant Use Disorder

On March 10, 2020, FDA is hosting a public meeting on Patient-Focused Drug Development (PFDD) for Stimulant Use Disorder. This meeting will provide FDA the opportunity to obtain input from individuals who are struggling or have struggled with the use of cocaine, methamphetamine, crystal meth, or misuse of prescription stimulants such as Adderall or Ritalin. Family members, advocates, caregivers and other stakeholders are encouraged to participate and share their views on the condition. In particular, FDA is interested in hearing perspectives on the: Health effects and daily impacts of their condition Impact (if any) of opioid and polysubstance use on their condition Treatment goals Decision factors considered when seeking out or selecting a treatment You may attend in-person or virtually. This event is FREE.

Register